Back to Agenda
Session 1 Biosimilars and Non-Originator Biologics (NOBs) Market Developments
Session Chair(s)
Steffen Thirstrup, MD, PhD
Chief Medical Officer
European Medicines Agency, Netherlands
Biosimilar market is developing both in Europe and globally with an increasing demand for biotherapeutics. The first biosimilar was approved in the EU in 2006 and FDA approved the first in in the US in early March this year. The session looks into the trends in different regions over the past years and also discusses the market access and pricing.
Speaker(s)
Global Market Development of Biosimilars and Non-Originator Biologics in Emerging Markets
Per Troein, MBA, MSc
IQVIA, United Kingdom
VP Strategic Partners
Outcome of the October EC workshop on Access to and Uptake of Biosimilars
Hilda Juhász
European Commission, Belgium
Policy Officer
European Generics and Biosimilar Medicines Association's view on market developments
Pieter Dylst, DrPH, MPharm, RPh
Medicines For Europe, Belgium
Senior Manager Market Access & Value Added Medicines
European Biopharmaceutical Enterprises and EFPIA's view on market developments
Alexander Roediger, MA, MBA
MSD Sharp and Dohme GmbH, Switzerland
Executive Director EMEAC Oncology Policy
Have an account?